Pharmacogenomic Effect/ADR for Clopidogrel (DBSNPE000176)

Identifier
DBSNPE000176
Drug
Clopidogrel (DB00758)
Interacting Gene/Enzyme
Cytochrome P450 2C19
Gene Name
CYP2C19
UniProt ID
P33261
Defining Change(s)
G > Ars4244285
Allele Name
CYP2C19*2
Genotype(s)
(A;A) / (A;G)
Type(s)
Effect Directly Studied
Groups
Non-functional CYP2C19
Description
Patients with this genotype have reduced metabolism of clopidogrel resulting in reduced plasma concentrations of its active metabolite.
References
  1. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994 Jun 3;269(22):15419-22. [PubMed:8195181]
  2. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009 Aug 26;302(8):849-57. doi: 10.1001/jama.2009.1232. [PubMed:19706858]